Literature DB >> 34189948

Indications for and contraindications of immune checkpoint inhibitors in cancer patients with coronavirus disease 2019 vaccination.

Bangyu Luo1, Jixi Li1, Xianhua Hou2, Qiao Yang3, Yi Zhou1, Jun Ye4, Xiaocheng Wu5, Yimei Feng6, Tianyu Hu7, Zhi Xu8, Ying He9, Jianguo Sun1.   

Abstract

The novel coronavirus disease 2019 (COVID-19) pandemic has lasted over 1 year and will not disappear in a short time. There is no specific remedy against the virus as yet. Vaccination is thus far one of the most important strategies for preventing COVID-19. Cancer patients with COVID-19 have a higher mortality because of immunosuppression. Immune checkpoint inhibitors (ICIs) are a novel anticancer strategy for blocking inhibitory pathways, which are related to the immune response. There is a question regarding whether COVID-19 vaccination and ICI treatment impact each other in cancer patients. This review explores both sides of the relationship between ICI treatment and COVID-19 vaccination and suggests good efficacy and safety of ICI treatment after COVID-19 vaccination as well as little impact on the virus protection and toxicity associated with COVID-19 vaccination during ICI treatment.

Entities:  

Keywords:  COVID-19; cancer; efficacy; immune checkpoint inhibitor; vaccination

Year:  2021        PMID： 34189948     DOI： 10.2217/fon-2021-0288

Source DB:  PubMed          Journal:  Future Oncol        ISSN： 1479-6694            Impact factor:   3.404


  9 in total

1.  Solid cancer patients achieve adequate immunogenicity and low rate of severe adverse events after SARS-CoV-2 vaccination.

Authors:  Urska Janzic; Urska Bidovec-Stojkovic; Katja Mohorcic; Loredana Mrak; Nina Fokter Dovnik; Marija Ivanovic; Maja Ravnik; Marina Caks; Erik Skof; Jerneja Debeljak; Peter Korosec; Matija Rijavec
Journal:  Future Oncol       Date:  2022-06-09       Impact factor: 3.674

Review 2.  Update on Immune Checkpoint Inhibitor Enterocolitis.

Authors:  Molly R Kelly-Goss; Yousef R Badran; Michael Dougan
Journal:  Curr Gastroenterol Rep       Date:  2022-10-20

3.  Chemo-Immunotherapy Regimes for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-Analysis and Cost-Effectiveness Analysis.

Authors:  Youwen Zhu; Kun Liu; Dong Ding; Kailing Wang; Xiaoting Liu; Xiao Tan
Journal:  Front Pharmacol       Date:  2022-05-20       Impact factor: 5.988

4.  Short-term safety of an anti-severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine for patients with advanced lung cancer treated with anticancer drugs: A multicenter, prospective, observational study.

Authors:  Tomoki Tamura; Kiichiro Ninomiya; Toshio Kubo; Shoichi Kuyama; Sayaka Tachibana; Koji Inoue; Kenichi Chikamori; Kenichiro Kudo; Nobuaki Ochi; Daijiro Harada; Yoshinobu Maeda; Katsuyuki Kiura
Journal:  Thorac Cancer       Date:  2021-12-28       Impact factor: 3.500

5.  Immune checkpoint blocking impact and nomogram prediction of COVID-19 inactivated vaccine seroconversion in patients with cancer: a propensity-score matched analysis.

Authors:  Yifei Ma; Nianqi Liu; Youlong Wang; Jiling Zeng; Ying-Ying Hu; Wu Hao; Huazheng Shi; Pengfei Zhu; Jun Lv; Wei Fan; Xinjia Wang
Journal:  J Immunother Cancer       Date:  2021-11       Impact factor: 13.751

Review 6.  Dosing Regimens of Immune Checkpoint Inhibitors: Attempts at Lower Dose, Less Frequency, Shorter Course.

Authors:  Mengjie Jiang; Yujie Hu; Gang Lin; Chao Chen
Journal:  Front Oncol       Date:  2022-06-20       Impact factor: 5.738

7.  Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Melanoma Treated with Immunotherapy.

Authors:  Panagiotis T Diamantopoulos; Christina-Nefeli Kontandreopoulou; Aikaterini Gkoufa; Elena Solomou; Amalia Anastasopoulou; Eleni Palli; Panagiotis Kouzis; Spyros Bouros; Mihalis Samarkos; Gkikas Magiorkinis; Helen Gogas
Journal:  Cancers (Basel)       Date:  2022-08-04       Impact factor: 6.575

8.  Changes in Behavior After Vaccination and Opinions Toward Mask Wearing: Thoracic Oncology Patient-Reported Experiences During the COVID-19 Pandemic.

Authors:  Toki Bolt; Amanda Tufman; Laura Sellmer; Kathrin Kahnert; Pontus Mertsch; Julia Kovács; Diego Kauffmann-Guerrero; Dieter Munker; Farkhad Manapov; Christian Schneider; Juergen Behr; Julia Walter
Journal:  Clin Med Insights Oncol       Date:  2022-09-27

9.  Severe immune thrombocytopenia following COVID-19 vaccination (Moderna) and immune checkpoint inhibitor.

Authors:  Kah-Meng Chong; Ching-Yao Yang; Chien-Chin Lin; Wan-Ching Lien
Journal:  Am J Emerg Med       Date:  2022-03-18       Impact factor: 4.093
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.